The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants

Marc A. Mergy, Raajaram Gowrishankar, Paul J. Gresch, Stephanie C. Gantz, John Williams, Gwynne L. Davis, C. Austin Wheeler, Gregg D. Stanwood, Maureen K. Hahn, Ry D. Blakely

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Despite the critical role of the presynaptic dopamine (DA) transporter (DAT, SLC6A3) in DA clearance and psychostimulant responses, evidence that DAT dysfunction supports risk for mental illness is indirect. Recently, we identified a rare, nonsynonymous Slc6a3 variant that produces the DAT substitution Ala559Val in two male siblings who share a diagnosis of attention-deficit hyperactivity disorder (ADHD), with other studies identifying the variant in subjects with bipolar disorder (BPD) and autism spectrum disorder (ASD). Previously, using transfected cell studies, we observed that although DAT Val559 displays normal total and surface DAT protein levels, and normal DA recognition and uptake,the variant transporter exhibits anomalous DA efflux (ADE) and lacks capacity for amphetamine (AMPH)-stimulated DA release. To pursue the significance of these findings in vivo, we engineered DAT Val559 knock-in mice, and here we demonstrate in this model the presence of elevated extracellular DA levels, altered somatodendritic and presynaptic D2 DA receptor (D2R) function, a blunted ability of DA terminals to support depolarization and AMPHevoked DA release, and disruptions in basal and psychostimu-lantevoked locomotor behavior. Together, our studies demonstrate an in vivo functional impact of the DAT Val559 variant,providing support for the ability of DAT dysfunction to impact risk for mental illness.

Original languageEnglish (US)
Pages (from-to)E4779-E4788
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number44
DOIs
StatePublished - Nov 4 2014

Fingerprint

Dopamine
Neurons
Aptitude
Dopamine Plasma Membrane Transport Proteins
Dopamine D2 Receptors
Amphetamine
Attention Deficit Disorder with Hyperactivity
Bipolar Disorder
Membrane Proteins

Keywords

  • Dopamine
  • Mouse
  • Polymorphism
  • Transgenic
  • Transporter

ASJC Scopus subject areas

  • General

Cite this

The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants. / Mergy, Marc A.; Gowrishankar, Raajaram; Gresch, Paul J.; Gantz, Stephanie C.; Williams, John; Davis, Gwynne L.; Wheeler, C. Austin; Stanwood, Gregg D.; Hahn, Maureen K.; Blakely, Ry D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 44, 04.11.2014, p. E4779-E4788.

Research output: Contribution to journalArticle

Mergy, Marc A. ; Gowrishankar, Raajaram ; Gresch, Paul J. ; Gantz, Stephanie C. ; Williams, John ; Davis, Gwynne L. ; Wheeler, C. Austin ; Stanwood, Gregg D. ; Hahn, Maureen K. ; Blakely, Ry D. / The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 44. pp. E4779-E4788.
@article{50b368f79da847c09343a38f12959dca,
title = "The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants",
abstract = "Despite the critical role of the presynaptic dopamine (DA) transporter (DAT, SLC6A3) in DA clearance and psychostimulant responses, evidence that DAT dysfunction supports risk for mental illness is indirect. Recently, we identified a rare, nonsynonymous Slc6a3 variant that produces the DAT substitution Ala559Val in two male siblings who share a diagnosis of attention-deficit hyperactivity disorder (ADHD), with other studies identifying the variant in subjects with bipolar disorder (BPD) and autism spectrum disorder (ASD). Previously, using transfected cell studies, we observed that although DAT Val559 displays normal total and surface DAT protein levels, and normal DA recognition and uptake,the variant transporter exhibits anomalous DA efflux (ADE) and lacks capacity for amphetamine (AMPH)-stimulated DA release. To pursue the significance of these findings in vivo, we engineered DAT Val559 knock-in mice, and here we demonstrate in this model the presence of elevated extracellular DA levels, altered somatodendritic and presynaptic D2 DA receptor (D2R) function, a blunted ability of DA terminals to support depolarization and AMPHevoked DA release, and disruptions in basal and psychostimu-lantevoked locomotor behavior. Together, our studies demonstrate an in vivo functional impact of the DAT Val559 variant,providing support for the ability of DAT dysfunction to impact risk for mental illness.",
keywords = "Dopamine, Mouse, Polymorphism, Transgenic, Transporter",
author = "Mergy, {Marc A.} and Raajaram Gowrishankar and Gresch, {Paul J.} and Gantz, {Stephanie C.} and John Williams and Davis, {Gwynne L.} and Wheeler, {C. Austin} and Stanwood, {Gregg D.} and Hahn, {Maureen K.} and Blakely, {Ry D.}",
year = "2014",
month = "11",
day = "4",
doi = "10.1073/pnas.1417294111",
language = "English (US)",
volume = "111",
pages = "E4779--E4788",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "44",

}

TY - JOUR

T1 - The rare DAT coding variant Val559 perturbs da neuron function, changes behavior, and alters in vivo responses to psychostimulants

AU - Mergy, Marc A.

AU - Gowrishankar, Raajaram

AU - Gresch, Paul J.

AU - Gantz, Stephanie C.

AU - Williams, John

AU - Davis, Gwynne L.

AU - Wheeler, C. Austin

AU - Stanwood, Gregg D.

AU - Hahn, Maureen K.

AU - Blakely, Ry D.

PY - 2014/11/4

Y1 - 2014/11/4

N2 - Despite the critical role of the presynaptic dopamine (DA) transporter (DAT, SLC6A3) in DA clearance and psychostimulant responses, evidence that DAT dysfunction supports risk for mental illness is indirect. Recently, we identified a rare, nonsynonymous Slc6a3 variant that produces the DAT substitution Ala559Val in two male siblings who share a diagnosis of attention-deficit hyperactivity disorder (ADHD), with other studies identifying the variant in subjects with bipolar disorder (BPD) and autism spectrum disorder (ASD). Previously, using transfected cell studies, we observed that although DAT Val559 displays normal total and surface DAT protein levels, and normal DA recognition and uptake,the variant transporter exhibits anomalous DA efflux (ADE) and lacks capacity for amphetamine (AMPH)-stimulated DA release. To pursue the significance of these findings in vivo, we engineered DAT Val559 knock-in mice, and here we demonstrate in this model the presence of elevated extracellular DA levels, altered somatodendritic and presynaptic D2 DA receptor (D2R) function, a blunted ability of DA terminals to support depolarization and AMPHevoked DA release, and disruptions in basal and psychostimu-lantevoked locomotor behavior. Together, our studies demonstrate an in vivo functional impact of the DAT Val559 variant,providing support for the ability of DAT dysfunction to impact risk for mental illness.

AB - Despite the critical role of the presynaptic dopamine (DA) transporter (DAT, SLC6A3) in DA clearance and psychostimulant responses, evidence that DAT dysfunction supports risk for mental illness is indirect. Recently, we identified a rare, nonsynonymous Slc6a3 variant that produces the DAT substitution Ala559Val in two male siblings who share a diagnosis of attention-deficit hyperactivity disorder (ADHD), with other studies identifying the variant in subjects with bipolar disorder (BPD) and autism spectrum disorder (ASD). Previously, using transfected cell studies, we observed that although DAT Val559 displays normal total and surface DAT protein levels, and normal DA recognition and uptake,the variant transporter exhibits anomalous DA efflux (ADE) and lacks capacity for amphetamine (AMPH)-stimulated DA release. To pursue the significance of these findings in vivo, we engineered DAT Val559 knock-in mice, and here we demonstrate in this model the presence of elevated extracellular DA levels, altered somatodendritic and presynaptic D2 DA receptor (D2R) function, a blunted ability of DA terminals to support depolarization and AMPHevoked DA release, and disruptions in basal and psychostimu-lantevoked locomotor behavior. Together, our studies demonstrate an in vivo functional impact of the DAT Val559 variant,providing support for the ability of DAT dysfunction to impact risk for mental illness.

KW - Dopamine

KW - Mouse

KW - Polymorphism

KW - Transgenic

KW - Transporter

UR - http://www.scopus.com/inward/record.url?scp=84914695673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914695673&partnerID=8YFLogxK

U2 - 10.1073/pnas.1417294111

DO - 10.1073/pnas.1417294111

M3 - Article

C2 - 25331903

AN - SCOPUS:84914695673

VL - 111

SP - E4779-E4788

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 44

ER -